Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,373,616
  • Shares Outstanding, K 5,597,694
  • Annual Sales, $ 41,908 M
  • Annual Income, $ 9,616 M
  • 60-Month Beta 0.73
  • Price/Sales 5.22
  • Price/Cash Flow 12.56
  • Price/Book 3.21
Trade PFE with:

Options Overview

Details
  • Implied Volatility 17.69%
  • Historical Volatility 17.64%
  • IV Percentile 6%
  • IV Rank 2.37%
  • IV High 60.64% on 12/09/20
  • IV Low 16.65% on 06/11/21
  • Put/Call Vol Ratio 0.58
  • Today's Volume 88,541
  • Volume Avg (30-Day) 91,239
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 1,887,524
  • Open Int (30-Day) 2,102,742

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.96
  • Number of Estimates 5
  • High Estimate 1.01
  • Low Estimate 0.90
  • Prior Year 0.78
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.47 +1.86%
on 06/08/21
40.72 -3.76%
on 06/10/21
-0.62 (-1.56%)
since 05/24/21
3-Month
35.25 +11.18%
on 03/25/21
41.09 -4.62%
on 05/05/21
+3.58 (+10.05%)
since 03/24/21
52-Week
31.61 +23.98%
on 06/26/20
43.08 -9.03%
on 12/09/20
+7.00 (+21.75%)
since 06/24/20

Most Recent Stories

More News
Antiepileptic Drugs Market Research Report 2021-2030 By Players, Regions, Product Types And Applications

In a recent published report, Kenneth Research has updated the market report for Antiepileptic Drugs Market for 2021 till 2030. Report further now discusses; the various strategies to be adopted or being...

ABT : 111.70 (+0.78%)
GSK : 39.70 (-0.38%)
NVS : 92.46 (+0.08%)
PFE : 39.19 (+0.36%)
VRX.TO : 30.80 (-3.33%)
Specialty Generics Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2021-2028

In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Specialty Generics in a special period....

AKRX : 0.0900 (-51.01%)
ENDP : 4.89 (+3.38%)
PFE : 39.19 (+0.36%)
VRX.TO : 30.80 (-3.33%)
Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study

Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.

AZN : 58.42 (+0.76%)
GSK : 39.70 (-0.38%)
PFE : 39.19 (+0.36%)
CLVS : 6.29 (+1.94%)
J&J (JNJ)/Bayer Seek Nod for Xarelto for Blood Clots in Kids

J&J (JNJ) and its partner Bayer seek approval of Xarelto as a treatment and prevention for venous thromboembolism in pediatric patients.

BMY : 65.85 (+0.90%)
JNJ : 163.37 (+0.46%)
PFE : 39.19 (+0.36%)
BAYRY : 15.3500 (+1.05%)
Thinking about trading options or stock in Eli Lilly, Pfizer, Penn National Gaming, CBS Corp, or First Solar?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LLY, PFE, PENN, VIAC, and FSLR.

FSLR : 84.51 (+5.39%)
PENN : 76.50 (-0.39%)
VIAC : 42.87 (+2.46%)
LLY : 232.97 (+7.31%)
PFE : 39.19 (+0.36%)
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data

EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.

SNY : 52.32 (+0.46%)
AZN : 58.42 (+0.76%)
GSK : 39.70 (-0.38%)
JNJ : 163.37 (+0.46%)
PFE : 39.19 (+0.36%)
MRK : 76.36 (+1.03%)
LLY : 232.97 (+7.31%)
Pfizer Declares Third-Quarter 2021 Dividend

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent third-quarter 2021 dividend on the company's common stock, payable September 7, 2021, to holders of the Common Stock...

PFE : 39.19 (+0.36%)
Pain Relief Therapeutics Market 2021 Opportunity Assessment, Business Opportunities, Top Industry Players, Trend and Growth to 2027

ABT : 111.70 (+0.78%)
ACRX : 1.3700 (+1.48%)
ACOR : 5.01 (+2.24%)
AXSM : 70.51 (+1.19%)
BAYRY : 15.3500 (+1.05%)
BDRFF : 119.0500 (+0.89%)
BDSI : 3.70 (+3.35%)
BMY : 65.85 (+0.90%)
COLL : 24.15 (+2.07%)
DEPO : 7.30 (+1.67%)
DRRX : 1.7000 (+1.19%)
EGLT : 0.0315 (-63.37%)
LLY : 232.97 (+7.31%)
FLXN : 9.22 (+3.25%)
GLPG : 68.86 (-0.52%)
HRTX : 15.79 (-3.84%)
KMPH : 14.25 (-0.35%)
MRK : 76.36 (+1.03%)
MESO : 8.45 (+0.72%)
NKTR : 17.02 (+2.10%)
NVS : 92.46 (+0.08%)
ORXOY : 4.5250 (-7.84%)
PFE : 39.19 (+0.36%)
REGN : 544.45 (+2.77%)
VRX.TO : 30.80 (-3.33%)
The 2 Best Pharma Stocks to Buy on Dips

Pharma companies with approved COVID-19 vaccines in their portfolios should grow significantly in the coming months, driven by large-scale vaccination programs around the globe. Thus, we think buying Johnson...

JNJ : 163.37 (+0.46%)
PFE : 39.19 (+0.36%)
Forget Dogecoin: These Growth Stocks Are a Smarter Bets

Because governments worldwide are expected to eventually crack down on cryptocurrencies—emulating China’s actions, due to concerns over massive energy consumption and illegal activities facilitated...

PFE : 39.19 (+0.36%)
AVGO : 470.06 (+0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

3rd Resistance Point 39.59
2nd Resistance Point 39.47
1st Resistance Point 39.33
Last Price 39.19
1st Support Level 39.06
2nd Support Level 38.94
3rd Support Level 38.80

See More

52-Week High 43.08
Last Price 39.19
Fibonacci 61.8% 38.70
Fibonacci 50% 37.34
Fibonacci 38.2% 35.99
52-Week Low 31.61

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar